🇺🇸 Empagliflozin Tablets in United States

11 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Diarrhoea — 2 reports (18.18%)
  2. Blood Glucose Fluctuation — 1 report (9.09%)
  3. Blood Glucose Increased — 1 report (9.09%)
  4. Cardiac Failure — 1 report (9.09%)
  5. Gastritis Erosive — 1 report (9.09%)
  6. Gastrooesophageal Reflux Disease — 1 report (9.09%)
  7. Glycosylated Haemoglobin Increased — 1 report (9.09%)
  8. Lipase Increased — 1 report (9.09%)
  9. Magnetic Resonance Imaging Abnormal — 1 report (9.09%)
  10. Oesophagitis — 1 report (9.09%)

Source database →

Empagliflozin Tablets in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Empagliflozin Tablets approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Empagliflozin Tablets in United States?

Kobe University is the originator. The local marketing authorisation holder may differ — check the official source linked above.